Clinical Research Directory

Inclusion Criteria: 1. Aged 18 to 85 years, gender not restricted; 2. Rutherford grade 2 to 5 3. Target lesions located in the superficial femoral artery (SFA) and/or proximal popliteal artery requiring percutaneous transluminal angioplasty (PTA), with the following characteristics: * Diameter stenosis ≥70% by visual estimation or * Chronic total occlusion (CTO) 4. At least one native below-the-knee artery supplying the foot on the affected side preoperatively; 5. The guidewire can successfully pass through the target lesion site within the vascular lumen; 6. Agree to participate in this clinical study and voluntarily sign the informed consent form. Exclusion Criteria: 1. Absence of proximal inflow tract or persistent lack of proximal inflow after pretreatment 2. Type D or higher dissection occurring after target lesion predilation; 3. Residual diameter stenosis \>50% following target lesion predilation; 4. Patients with known allergies to aspirin, clopidogrel, heparin, paclitaxel, contrast agents, etc.; 5. Abnormal function of vital organs (liver/kidney/brain) deemed unsuitable for intervention by investigators; 6. Documented allergy to aspirin, clopidogrel, heparin, paclitaxel/structural analogs, or contrast agents; 7. Patients currently undergoing dialysis or immunosuppressive therapy; 8. Presence of detectable thrombus in lower extremity arteries requiring intraoperative thrombolysis; 9. History of stroke or ST-elevation myocardial infarction within 6 months prior to procedure; 10. Pregnancy or lactation women; 11. Currently participation in other drug/medical device clinical trials without completion; 12. Patients deemed by the investigator to be unsuitable for participation in this study.